Fabrication of Fe₃O₄@PVA microspheres by one-step electrospray for magnetic resonance imaging during transcatheter arterial embolization.

Abstract

Magnetic resonance imaging (MRI) has attracted increasing attention as a feasible alternative or adjunctive imaging modality for X-ray digital subtraction angiography because of the high tissue resolution and non-ionization radiation. In this study, a one-step electrospray method was developed to fabricate PVA microspheres encapsulated with in situ synthesized Fe₃O₄ nanoparticles. Fe₃O₄@PVA microspheres were mono-dispersed black spheres with a wide range of sizes (262-958 µm). The in situ-synthesized Fe₃O₄ nanoparticles were used as the contrast agent of MRI and the cross-linkers of PVA matrixes for the embolization purpose. In vivo evaluation of renal arteries of normal rabbits showed that Fe₃O₄@PVA microspheres had good embolic effect and enhanced capability of MRI. In vitro and in vivo biosafety assessment confirmed that Fe₃O₄@PVA microspheres had favorable biocompatibility. The DOX-loaded Fe₃O₄@PVA microspheres showed a typical drug-sustained release profile. These results suggest that the prepared DOX-loaded Fe₃O₄@PVA microspheres have the function of MRI, embolotherapy and chemotherapy. We expect our study could provide a simple and useful approach for the systematic design, fabrication, and application of a new type of magnetic microspheres as a triple-functional embolic agent for the development of MRI-guided TACE. STATEMENT OF SIGNIFICANCE: Due to the low tissue resolution and hazardous ionization radiation of X-ray digital subtraction angiography, it is beneficial to study MR imaging embolic microspheres for the development of MRI-guided TACE. In this study, a one-step electrospray method was firstly developed to fabricate PVA microspheres encapsulated with in situ synthesized Fe₃O₄ nanoparticles. Then, chemotherapeutic agent (DOX), contrast media of MRI (Fe₃O₄) and embolic agent (PVA matrix) were combined together in one body (DOX-loaded Fe₃O₄@PVA microspheres) to achieve the triple effects of chemotherapy, MR imaging and embolization. This triple-functional embolic agent offers potential for the future development of MRI-guided TACE.